|Type||Public (JSE: APN)
|Industry||Health care, pharmaceuticals|
|Founded||1850, public 1997|
|Headquarters||Durban, South Africa|
|Key people||Stephen Saad (Group Chief Executive)|
|Products||Pharmaceuticals and health care|
|Revenue||R12.4 billion (FY 2011)|
|Profit||R5.6 billion (FY 2011)|
|Total assets||R26.8 billion (FY 2011)|
|Total equity||R13.3 billion (FY 2011)|
After complaints of anticompetitive activities by Boehringer Ingelheim and GlaxoSmithKline in 2003, Aspen was granted licenses from the companies to create generic versions of antiretrovirals (ARV) for use in the Sub-Saharan portion of Africa. At the time, Aspen was already the largest generic medicine distributor in South Africa. Subsequent inspections by international organizations led to a rapid increase in distribution capabilities, primarily though integration with alliance partners. The company's efforts led to expanded access to affordable treatments for HIV/AIDS.
- "Aspen Pharmacare Holdings Limited Annual Report 2011". Aspen Holdings. Retrieved 30 June 2012.
- ASPEN Corporate Office Durban, retrieved 1 July 2012
- APN Profile & Executives - Aspen Pharmacare Holdings Ltd - Bloomberg
- Aspen Pharmacare Offers to Buy Australia's Sigma Pharma for $1.23 Billion - Bloomberg
- Ricardo Meléndez-Ortiz; Pedro Roffe (1 January 2009). Intellectual Property and Sustainable Development: Development Agendas in a Changing World. Edward Elgar Publishing. pp. 178–. ISBN 978-1-84844-645-8. Retrieved 30 June 2012.
- Patrick Lumumba Osewe; Yvonne Korkoi Nkrumah; Emmanuel K. Sackey (15 June 2008). Improving Access to HIV/AIDS Medicines in Africa: Trade-Related Aspects of Intellectual Property Rights (TRIPS) Flexibilities Utilization. World Bank Publications. pp. 35–39. ISBN 978-0-8213-7544-0. Retrieved 30 June 2012.
- Céline Louche; Samuel O. Idowu; Walter Leal Filho (30 April 2010). Innovative Csr: From Risk Management to Value Creation. Greenleaf Publishing. pp. 158–. ISBN 978-1-906093-35-8. Retrieved 30 June 2012.